The use of generic DAAs for hepatitis C treatment, Freeman et al 2016

The use of generic DAAs for hepatitis C treatment, Freeman et al 2016

Download PDF

/ News

Share the Post

Related Posts

2018 IAS Brief Document Ending an Epidemic – Prioritizing People Who Inject Drugs in HCV elimination Efforts.
Patent Situation of The Key Product for Treatment of Hepatitis C: DACLASTAVIR – WHO working paper, revised version, Oct 2014
Pricing of Indian generic sofosbuvir, 30th Jan,2016
Patient Groups and CSOs in Asia written a letter to Indian Government to Request Waiver on Local Clinical Trial for The Coming Generic DAAs
Read More
Story from Ayu Oktariani, Bandung, Indonesia
APN+ joins MTAAG in congratulating Malaysia on sofosbuvir compulsory license
Letter from Community in Asia and Eastern Europe to Global Fund Board for Financing Hep C Treatment
A two pager of what you need to know of Sofosbuvir